Synta Pharmaceuticals Corp.  

(Public, NASDAQ:SNTA)   Watch this stock  
Find more results for SNTA
2.18
-0.02 (-0.91%)
Jul 2 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.13 - 2.22
52 week 1.85 - 4.97
Open 2.19
Vol / Avg. 1.35M/1.27M
Mkt cap 295.73M
P/E     -
Div/yield     -
EPS -0.80
Shares 134.42M
Beta 2.37
Inst. own 27%
Aug 4, 2015
Q2 2015 Synta Pharmaceuticals Corp Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jun 24, 2015
Synta Pharmaceuticals Corp at ROTH Healthcare Day - London
Jun 23, 2015
Synta Pharmaceuticals Corp at JMP Securities Life Sciences Conference
Jun 3, 2015
Synta Pharmaceuticals Corp at Jefferies Global Healthcare Conference
May 7, 2015
Q1 2015 Synta Pharmaceuticals Corp Earnings Call - Webcast
May 7, 2015
Q1 2015 Synta Pharmaceuticals Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -92.25% -87.97%
Return on average equity -149.28% -150.86%
Employees 110 -
CDP Score - -

Address

45 HARTWELL AVE
LEXINGTON, MA 2421
United States - Map
+1-781-2748200 (Phone)
+1-781-2748228 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Synta Pharmaceuticals Corp. is a biopharmaceutical company. The Company focuses on research, development and commercialization of oncology medicines for cancer patients. Its lead oncology drug candidate is ganetespib, which is a heat shock protein 90 (Hsp90) inhibitor. The Company also has an additional clinical-stage oncology candidate: elesclomol, which is a mitochondrial metabolism inhibitor. Ganetespib is a small molecule inhibitor of Hsp90, which is a molecular chaperone required for the folding and activation of cancer-promoting proteins. Elesclomol is a first-in-class investigational drug candidate that triggers programmed cell death (apoptosis) in cancer cells through a mechanism: disrupting cancer cell energy metabolism. The Company entered into a license arrangement for its calcium release-activated calcium channel (CRACM) program, including two candidates and the associated intellectual property portfolio, with PRCL Research Inc. (PRCL).

Officers and directors

Keith R. Gollust Chairman of the Board
Age: 69
Bio & Compensation  - Reuters
Chen Schor President, Chief Executive Officer, Director
Age: 42
Bio & Compensation  - Reuters
Marc R. Schneebaum Chief Financial Officer, Senior Vice President
Age: 60
Bio & Compensation  - Reuters
Wendy E. Rieder Esq. Senior Vice President, General Counsel
Age: 47
Bio & Compensation  - Reuters
Arthur McMahon Senior Vice President - Human Resources
Age: 69
Bio & Compensation  - Reuters
Vojo Vukovic M.D., Ph.D. Senior Vice President, Chief Medical Officer
Age: 48
Bio & Compensation  - Reuters
Paul A. Friedman M.D. Independent Director
Age: 72
Bio & Compensation  - Reuters
Bruce Kovner Independent Director
Age: 70
Bio & Compensation  - Reuters
Donald W. Kufe M.D. Independent Director
Age: 70
Bio & Compensation  - Reuters
William S. Reardon CPA Independent Director
Age: 68
Bio & Compensation  - Reuters